作为全球最大资产管理巨头之一，贝莱德2022年一季末管理资产规模约为9.57万亿美元，远超我国 公募基金行业总规模26万亿元的历史新高。其自主开发的风险管理系统阿拉丁（Aladdin）就是"秘 密"武器，Aladdin由Asset（资产）、Liability（负债）、Debt（债务）、Derivative Investment network （衍生品投资网络）的首字母缩写构成，已成为其核心竞争力所在，受到越来越多机构投资者的认可， 最终反哺自身业务。2021年，贝莱德以阿拉丁为核心的技术和风险管理收入高达12.81亿美元，占总营 业收入的比例达6.6%。 受此启发，申万菱信基金董事长陈晓升自掌舵公司第一天起，就立志为申万菱信打造一套属于自己 的"阿拉丁"系统，以期作为打造具有申万菱信特色的体系化资产管理机构的重要抓手。"每个人在机构 都是一个过客，或长或短。机构需要有一套东西来承载投研风控团队所有过往工作的成果，变为机构共 有，从而快速提升整个投研风控团队的能力，服务于投资业绩、策略开发和产品创设，这是从长期看很 有意义的一件事。"陈晓升说。 距离陈晓升履新近一年，申万菱信已高效构建了集研究、投资、风控于一 ...

谈及2021年投资运营情况，社保基金会相关负责人说，2021年，受新冠肺炎疫情全球大流行影响， 国内外宏观经济环境更趋严峻复杂，资本市场波动加剧，基金投资面临的风险挑战明显增多，管理运营 难度不断加大。社保基金会坚持以习近平新时代中国特色社会主义思想为指导，牢牢把握"国之大者"， 围绕服务国家重大战略和实现"双碳"目标开展投资，科学合理配置基金资产，积极把握市场结构性机会 开展动态配置，在确保基金安全和保值增值的基础上，更好发挥长期机构投资者重要作用，积极助力国 内资本市场稳定和健康发展。 市场人士认为，社保基金是社会保障的储备基金，其资金久期较长且规模较大，这些特性决定了社 保基金的投资风格以长期价值投资为主。 全国社会保障基金理事会发布的2021年社保基金年度报告显示，2021年，社保基金投资收益额达 1131.80亿元，投资收益率为4.27%。社保基金会相关负责人表示，社保基金会坚持长期投资、价值投资 和责任投资理念，按照审慎投资、安全至上、控制风险、提高收益的方针进行投资运营管理，确保基金 安全和保值增值。 去年投资收益率为4.27% 报告数据显示，社保基金自成立以来的年均投资收益率为8.30%，累计 ...

基金公司韭菜割到了自己人头上？ 爆料人表示，自己购买的基金是今年6月3日首发的申万菱信行业精选混合基金，基金经理是5月份，刚刚被挖到申万菱信的明星基金经理贾成东。 不过，凤凰网财经《投资观察》查询公开信息发现，贾成东并非今年5月才加入申万菱信，而是2024年12月就入职了，而且担任申万菱信副总经理。而申万 宏源证券的负责人和法定代表人的确名叫张剑，不知是否正是爆料人所说的集团领导。 今日，一份金融圈的内部人爆料在网上广为流传。据网传信息显示，爆料人为申万宏源证券一名基层员工。他自称为了完成集团领导张剑强压的政治任务， 购买了申万菱信新发的基金，结果"亏成狗"。他还愤怒地表示，"被公司羞辱智商、践踏尊严，投诉无门，不求能解决啥，就是曝光*的。"而申万宏源证券 是申万菱信的控股股东，持股比例达到67%。 "（申万菱信行业精选）两个月来每周净值都在跌，实际操作非常无厘头，与公司宣传时的高股息方向完全不符。"爆料人表示。他还怒斥，"贾成东就是一 赌狗风格，拿着大家的钱去重仓赌。员工在公司群里反馈希望给个说法，公司至今不闻不问。" 凤凰网财经《投资观察》也就此事件分别向申万宏源和申万菱信求证，但截至发稿暂未获得申万宏源 ...

Core Viewpoint - The recent announcement of subscription limits for the China Europe Medical Innovation Fund managed by Ge Lan highlights the strong rebound in the innovative drug sector, with significant year-to-date gains in related funds and stocks [1][2]. Fund Performance and Subscription Limits - The China Europe Medical Innovation Fund has seen a year-to-date return exceeding 60%, with its scale increasing to 8.1 billion yuan by the end of Q2 [1][4]. - Over 30 actively managed equity funds have announced subscription limits since July, indicating a cautious approach by fund managers in response to rapid inflows [2][7]. - The China Europe Medical Innovation Fund's performance is notable, but it has not recovered from significant losses over the past three years, with a decline of 9.62% [2][6]. Market Trends and Fund Management - The strong performance of the innovative drug sector is reflected in the China Securities Index's pharmaceutical and biotechnology index, which has risen over 20% in the past year [5]. - The subscription limits are intended to stabilize fund operations and protect the interests of existing investors, serving as a buffer against excessive short-term inflows [2][3]. - Other funds managed by prominent managers, such as the China Europe Digital Economy Fund and the China Europe Science and Technology Innovation Fund, have also implemented subscription limits to manage inflows effectively [2][3]. Fund Composition and Strategy - The China Europe Medical Innovation Fund has a heavy allocation in the pharmaceutical and biotechnology sector, with 91.62% of its holdings in this area, primarily in stocks like 3SBio, which has seen a nearly 400% increase this year [5][6]. - The fund's previous subscription limit was set at 5 million yuan per day, indicating a history of managing inflows carefully [5][6]. Broader Market Context - The recent trend of subscription limits among high-performing funds reflects a broader strategy to maintain fund performance and manage investor expectations amid a rising equity market [7][10]. - The market outlook suggests potential structural characteristics in A-shares, with expectations of continued recovery in risk appetite due to easing monetary policies and reduced global trade tensions [12].

Core Viewpoint - CITIC Securities Asset Management Co., Ltd. has officially changed the management of three collective asset management plans to Huaxia Fund Management Co., Ltd., effective from August 12, 2025, following the approval of the holders' meeting on June 24, 2025 [1][3]. Group 1: Product Change Information - The products involved include changes in name, management, investment manager, type, duration, fee structure, investment scope, and performance comparison benchmarks [1][3]. - The management change includes the transition from CITIC Securities Asset Management to Huaxia Fund Management [1][3]. - The investment strategy has been adjusted to include new investment types such as depositary receipts and financial derivatives [11][22][34]. Group 2: Fund Contract Effectiveness - The new fund contracts will take effect on August 12, 2025, rendering the original asset management contracts invalid [3][41]. - Holders of the original plans who do not redeem or transfer their holdings during the redemption period will have their shares automatically converted to the corresponding categories of the new public funds [3][42]. Group 3: Fee Structure Adjustments - The fee structure has been revised, including changes to redemption fees and service fees for different classes of shares [10][26][37]. - The minimum holding period restrictions for certain share classes have been removed, allowing for greater flexibility for investors [14][25][37]. Group 4: Investment Strategy Adjustments - The stock investment proportion has been adjusted from 50-95% to 60-95%, allowing for a more aggressive investment approach [15][38]. - The performance comparison benchmark has been modified to reflect a new weighting of indices [39].

8月11日，上证科创综指上涨1.75%，年内涨幅达22.51%，表现亮眼。华商上证科创板综合指数增强基 金经理海洋表示，作为代表中国科技创新的核心指数，上证科创综指展现出强劲的成长属性，随着市场 风险偏好提升，指数向上空间有望进一步打开。 由华商基金艾定飞博士和海洋博士联手管理的华商上证科创板综合指数增强基金，正是运用华商基金自 主研发的量化选股模型，在保持对上证科创板综合指数紧密跟踪的前提下，力争实现超越目标指数的投 资收益（来自基金法律文件，更多内容详阅法律文件）。 在科技强国的大趋势下，科创板有望成为未来牛市的核心战场之一。华商上证科创板综合指数增强基金 （A类：023897，C类：023898），科创板贝塔与主动管理阿尔法的深度融合，对于看好中国科技创新 的投资者而言，或是不错的高效布局工具。 自2019年创立以来，科创板即是服务国家科技战略的重要平台，汇聚了一批突破关键核心技术的创新企 业。最新数据显示，上证科创综指前五大权重行业分别为电子（41.6%）、医药（18.2%）、机械 （10.7%）、计算机（9.7%）和电力设备及新能源（6.7%），完美覆盖了半导体、创新药、人工智能、 机器人、低空经济 ...

1公告基本信息 ■ 注：为维护基金份额持有人的利益，华泰证券(上海)资产管理有限公司（以下简称"本基金管理人"）决 定自2025年8月13日单日每个基金账户累计申购及转换转入华泰紫金价值甄选混合型证券投资基金C份 额金额不超过人民币100元，若超过上述金额，本基金管理人有权部分或全部拒绝该笔申购申请。本基 金限制大额申购业务期间，本基金管理人将正常办理本基金的赎回业务。本基金恢复办理大额申购业务 的具体时间将另行公告。 2其他需要提示的事项 （1）投资人欲了解详细情况，可通过基金管理人网站https://www.htscamc.com查阅，如有任何疑问，可 致电本公司客户服务热线400-889-5597 咨询。 （2）风险提示：本基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金 一定盈利，也不保证最低收益。投资者投资各基金之前应认真阅读各基金的《基金合同》、《招募说明 书》、《基金产品资料概要》等相关法律文件。敬请投资者留意投资风险。 特此公告。 华泰证券(上海)资产管理有限公司 2025年8月12日 ...

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The fund is named "E Fund Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Enhanced Strategy ETF" and is a type of open-ended index fund [23] - The fund will be available for subscription from August 18 to August 22, 2025, with both online and offline cash subscription options [2][23] - The maximum fundraising scale for the fund is set at 2 billion RMB, excluding interest and subscription fees [5][23] Group 2 - Investors must have a Shanghai Stock Exchange A-share account or a securities investment fund account to subscribe to the fund [3][44] - The subscription fee for the fund will not exceed 0.80% of the subscribed amount [4][28] - The fund's investment objective is to pursue returns that exceed the performance benchmark while controlling the average tracking deviation and annualized tracking error [24][25] Group 3 - The fund's underlying index is the Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Index, which includes stocks listed on the Science and Technology Innovation Board [12][13] - The fund will be managed by E Fund Management Co., Ltd., with Ping An Bank as the custodian [1][64] - The fund's shares will be issued at an initial value of 1 RMB per share [23]

Group 1 - The fund name is "Southern Ruijing Mixed Securities Investment Fund" with A and C class shares [11] - The fund is a mixed-type open-ended securities investment fund [12] - The fund's initial share value is set at 1.00 RMB [13] Group 2 - The fundraising period is from August 25, 2025, to September 12, 2025 [5][16] - The minimum subscription amount for both initial and additional subscriptions is 1 RMB [6] - The fund is open to individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [5][14] Group 3 - The fund management company is Southern Fund Management Co., Ltd. [55] - The fund custodian is Industrial and Commercial Bank of China [57] - The fund will be sold through various sales institutions including banks and securities firms [15] Group 4 - The subscription fee for A class shares is up to 1.2%, decreasing with larger subscription amounts, while C class shares have no subscription fee [19] - The fund allows multiple subscriptions during the fundraising period, and once confirmed, subscriptions cannot be revoked [24] - Interest generated from valid subscription funds during the fundraising period will be converted into fund shares for the holders [52] Group 5 - The fund will be subject to a verification process to ensure it meets the conditions for registration, including a minimum of 200 investors and a total fundraising amount of at least 200 million RMB [16][53] - If the fundraising conditions are not met, the fund management will return the funds to investors with interest [54]